<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20250111011355&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20250111011355&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 11 Jan 2025 06:13:56 +0000</lastbuilddate>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39791537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>Development of specific therapies addressing the underlying diseases' mechanisms constitutes the basis of precision medicine. Transthyretin cardiac amyloidosis (ATTR-CM) is an exemplar of precise therapeutic approach in the field of heart failure and cardiomyopathies. A better understanding of the underlying pathophysiology, more precise data of its epidemiology, and advances in imaging techniques that allow non-invasive diagnosis have fostered the development of new and very effective specific...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 10:ehae811. doi: 10.1093/eurheartj/ehae811. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Development of specific therapies addressing the underlying diseases' mechanisms constitutes the basis of precision medicine. Transthyretin cardiac amyloidosis (ATTR-CM) is an exemplar of precise therapeutic approach in the field of heart failure and cardiomyopathies. A better understanding of the underlying pathophysiology, more precise data of its epidemiology, and advances in imaging techniques that allow non-invasive diagnosis have fostered the development of new and very effective specific therapies for ATTR-CM. Therapeutic advances have revolutionized the field, transforming a rare, devastating, and untreatable disease into a more common disease with several therapeutic alternatives available. Three main types of therapies (stabilizers, suppressors, and degraders) that act at different points of the amyloidogenic cascade have been developed or are currently under investigation. In this review, the key advances in pathophysiology and epidemiology that have occurred in the last decades along with the different therapeutic alternatives available or under development for ATTR-CM are described, illustrating the role of precision medicine applied to cardiovascular disorders. Pending questions that would need to be answered in upcoming years are also reviewed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39791537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39791537</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae811>10.1093/eurheartj/ehae811</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39791537</guid>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Esther Gonzalez-Lopez</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:date>2025-01-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine</dc:title>
<dc:identifier>pmid:39791537</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae811</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: programming the epicardium to cure broken hearts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39791536/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 10:ehae825. doi: 10.1093/eurheartj/ehae825. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39791536/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39791536</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae825>10.1093/eurheartj/ehae825</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39791536</guid>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Tatjana Dorn</dc:creator>
<dc:creator>Alessandra Moretti</dc:creator>
<dc:date>2025-01-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: programming the epicardium to cure broken hearts</dc:title>
<dc:identifier>pmid:39791536</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae825</dc:identifier>
</item>
<item>
<title>Mechanical circulatory support: when, how, and for whom</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39791535/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>Cardiogenic shock represents a critical condition in which the heart is unable to maintain adequate circulation leading to insufficient tissue perfusion and end-organ failure. Temporary mechanical circulatory support offers the potential to stabilize patients, provide a bridge-to-recovery, provide a bridge-to-decision, or facilitate definitive heart replacement therapies. Although randomized controlled trials have been performed in infarct-related cardiogenic shock and refractory cardiac arrest,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 10:ehae925. doi: 10.1093/eurheartj/ehae925. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiogenic shock represents a critical condition in which the heart is unable to maintain adequate circulation leading to insufficient tissue perfusion and end-organ failure. Temporary mechanical circulatory support offers the potential to stabilize patients, provide a bridge-to-recovery, provide a bridge-to-decision, or facilitate definitive heart replacement therapies. Although randomized controlled trials have been performed in infarct-related cardiogenic shock and refractory cardiac arrest, the optimal timing, appropriate patient selection, and optimal implementation of these devices remain complex and predominantly based on observational data and expert consensus, especially in non-ischaemic shock. This review explores the details of 'when, how, and for whom' temporary mechanical circulatory support devices should be used, examining specific clinical scenarios, the mechanisms by which they operate, and the patient populations that may benefit. The review also highlights the many gaps in evidence and need for better understanding of the interaction between human biology and these devices.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39791535/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39791535</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae925>10.1093/eurheartj/ehae925</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39791535</guid>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jacob Eifer Møller</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>David Morrow</dc:creator>
<dc:creator>Jesper Kjærgaard</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:date>2025-01-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mechanical circulatory support: when, how, and for whom</dc:title>
<dc:identifier>pmid:39791535</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae925</dc:identifier>
</item>
<item>
<title>Coronary atherosclerosis in athletes: emerging concepts and preventive strategies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39791533/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>There should be no assumption that an athlete is immune to coronary artery disease (CAD), even when traditional cardiovascular (CV) risk factors appear well-managed. Excelling in certain aspects of health does not equate to total CV protection. Recent data from cardiac imaging studies have raised the possibility that long-term, high-volume, high-intensity endurance exercise is associated with coronary atherosclerosis. Whilst the risk of CV events has not been shown to rise with athletic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 10:ehae927. doi: 10.1093/eurheartj/ehae927. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There should be no assumption that an athlete is immune to coronary artery disease (CAD), even when traditional cardiovascular (CV) risk factors appear well-managed. Excelling in certain aspects of health does not equate to total CV protection. Recent data from cardiac imaging studies have raised the possibility that long-term, high-volume, high-intensity endurance exercise is associated with coronary atherosclerosis. Whilst the risk of CV events has not been shown to rise with athletic activity, the potential for CAD should not be overlooked as it is the leading cause of sudden cardiac death in athletes >;35 years of age (i.e. 'Masters athletes'). Evaluating both traditional and non-traditional risk factors for CAD is the most important part of pre-participation evaluation in Masters athletes. When managing athletes at risk of CAD it is important to adopt a shared decision-making approach regarding lifestyle adaptation and lipid-lowering treatments. In the great majority of athletes, after excluding the presence of symptoms and inducible ischaemia, this advice should include encouragement to continue exercising as available data indicate that higher levels of fitness are associated with a markedly attenuated incidence of coronary events regardless of the severity of coronary disease. Future research is needed to establish the relationship between clinically relevant CAD outcomes and coronary artery calcification in Masters Athletes, the role of sex, as well as exploration of the mechanisms underpinning these unexpected CV adaptations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39791533/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39791533</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae927>10.1093/eurheartj/ehae927</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39791533</guid>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Guido Claessen</dc:creator>
<dc:creator>Thijs M H Eijsvogels</dc:creator>
<dc:creator>Christine M Albert</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Erin D Michos</dc:creator>
<dc:creator>Andre La Gerche</dc:creator>
<dc:date>2025-01-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary atherosclerosis in athletes: emerging concepts and preventive strategies</dc:title>
<dc:identifier>pmid:39791533</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae927</dc:identifier>
</item>
<item>
<title>Functional coronary assessment in angina with intermediate coronary stenosis: the #FullPhysiology approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39791532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 10:ehae926. doi: 10.1093/eurheartj/ehae926. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39791532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39791532</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae926>10.1093/eurheartj/ehae926</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39791532</guid>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Antonio Maria Leone</dc:creator>
<dc:creator>Domenico Galante</dc:creator>
<dc:creator>Andrea Viceré</dc:creator>
<dc:creator>Andrea Marrone</dc:creator>
<dc:creator>Filippo Maria Verardi</dc:creator>
<dc:creator>Chiara Giuliana</dc:creator>
<dc:creator>Ciro Pollio Benvenuto</dc:creator>
<dc:creator>Vincenzo Viccaro</dc:creator>
<dc:creator>Simona Todisco</dc:creator>
<dc:creator>Andrea Erriquez</dc:creator>
<dc:creator>Simone Biscaglia</dc:creator>
<dc:creator>Cristina Aurigemma</dc:creator>
<dc:creator>Enrico Romagnoli</dc:creator>
<dc:creator>Rocco Antonio Montone</dc:creator>
<dc:creator>Michele Basile</dc:creator>
<dc:creator>Eugenio Di Brino</dc:creator>
<dc:creator>Filippo Rumi</dc:creator>
<dc:creator>Gennaro Capalbo</dc:creator>
<dc:creator>Carlo Trani</dc:creator>
<dc:creator>Francesco Burzotta</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Italo Porto</dc:creator>
<dc:creator>Gianluca Campo</dc:creator>
<dc:date>2025-01-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Functional coronary assessment in angina with intermediate coronary stenosis: the #FullPhysiology approach</dc:title>
<dc:identifier>pmid:39791532</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae926</dc:identifier>
</item>
<item>
<title>Diagnostic utility of respiratory chain enzyme analysis in isolated mitochondrial cardiomyopathy mimicking hypertrophic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39791528/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 10:ehae920. doi: 10.1093/eurheartj/ehae920. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39791528/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39791528</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae920>10.1093/eurheartj/ehae920</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39791528</guid>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ryo Abe</dc:creator>
<dc:creator>Mitsunobu Kitamura</dc:creator>
<dc:creator>Morimasa Takayama</dc:creator>
<dc:date>2025-01-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Diagnostic utility of respiratory chain enzyme analysis in isolated mitochondrial cardiomyopathy mimicking hypertrophic cardiomyopathy</dc:title>
<dc:identifier>pmid:39791528</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae920</dc:identifier>
</item>
<item>
<title>Carotid artery atherosclerosis: mechanisms of instability and clinical implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39791527/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular disease remains a prominent cause of disability and premature death worldwide. Within this spectrum, carotid artery atherosclerosis is a complex and multifaceted condition, and a prominent precursor of acute ischaemic stroke and other cardiovascular events. The intricate interplay among inflammation, oxidative stress, endothelial dysfunction, lipid metabolism, and immune responses participates in the development of lesions, leading to luminal stenosis and potential plaque...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 10:ehae933. doi: 10.1093/eurheartj/ehae933. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease remains a prominent cause of disability and premature death worldwide. Within this spectrum, carotid artery atherosclerosis is a complex and multifaceted condition, and a prominent precursor of acute ischaemic stroke and other cardiovascular events. The intricate interplay among inflammation, oxidative stress, endothelial dysfunction, lipid metabolism, and immune responses participates in the development of lesions, leading to luminal stenosis and potential plaque instability. Even non-stenotic plaques can precipitate a sudden cerebrovascular event, regardless of the degree of luminal encroachment. In this context, carotid imaging modalities have proved their efficacy in providing in vivo characterization of plaque features, contributing substantially to patient risk stratification and clinical management. This review emphasizes the importance of identifying high-risk individuals by use of current imaging modalities, biomarkers, and risk stratification tools. Such approaches inform early intervention and the implementation of personalized therapeutic strategies, ultimately enhancing patient outcomes in the realm of cardiovascular disease management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39791527/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39791527</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae933>10.1093/eurheartj/ehae933</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39791527</guid>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Luca Saba</dc:creator>
<dc:creator>Riccardo Cau</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>M Eline Kooi</dc:creator>
<dc:creator>Daniel Staub</dc:creator>
<dc:creator>Gavino Faa</dc:creator>
<dc:creator>Terenzio Congiu</dc:creator>
<dc:creator>George Ntaios</dc:creator>
<dc:creator>Bruce A Wasserman</dc:creator>
<dc:creator>John Benson</dc:creator>
<dc:creator>Valentina Nardi</dc:creator>
<dc:creator>Rika Kawakami</dc:creator>
<dc:creator>Giuseppe Lanzino</dc:creator>
<dc:creator>Renu Virmani</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:date>2025-01-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Carotid artery atherosclerosis: mechanisms of instability and clinical implications</dc:title>
<dc:identifier>pmid:39791527</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae933</dc:identifier>
</item>
<item>
<title>Arterial NALCN Knock-Down Ameliorates Mineralocorticoid-Induced Hypertension and Arterial Over-Contractility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39791272/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 10. doi: 10.1161/CIRCRESAHA.124.325058. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39791272/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39791272</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325058>10.1161/CIRCRESAHA.124.325058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39791272</guid>
<pubDate>Fri, 10 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Hyeryeong Lee</dc:creator>
<dc:creator>Solah Park</dc:creator>
<dc:creator>Dong Jun Sung</dc:creator>
<dc:creator>Jin Ryeol An</dc:creator>
<dc:creator>Mi Seon Seo</dc:creator>
<dc:creator>Hyun Ju Noh</dc:creator>
<dc:creator>Jueng Soo You</dc:creator>
<dc:creator>Sung Hea Kim</dc:creator>
<dc:creator>Hana Cho</dc:creator>
<dc:creator>Bokyung Kim</dc:creator>
<dc:creator>Sang Woong Park</dc:creator>
<dc:creator>Young Min Bae</dc:creator>
<dc:date>2025-01-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Arterial NALCN Knock-Down Ameliorates Mineralocorticoid-Induced Hypertension and Arterial Over-Contractility</dc:title>
<dc:identifier>pmid:39791272</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325058</dc:identifier>
</item>
<item>
<title>Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39788123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>As the brain transitions from wakefulness to sleep, processing of external information diminishes while restorative processes, such as glymphatic removal of waste products, are activated. Yet, it is not known what drives brain clearance during sleep. We here employed an array of technologies and identified tightly synchronized oscillations in norepinephrine, cerebral blood volume, and cerebrospinal fluid (CSF) as the strongest predictors of glymphatic clearance during NREM sleep. Optogenetic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 17:S0092-8674(24)01343-6. doi: 10.1016/j.cell.2024.11.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">As the brain transitions from wakefulness to sleep, processing of external information diminishes while restorative processes, such as glymphatic removal of waste products, are activated. Yet, it is not known what drives brain clearance during sleep. We here employed an array of technologies and identified tightly synchronized oscillations in norepinephrine, cerebral blood volume, and cerebrospinal fluid (CSF) as the strongest predictors of glymphatic clearance during NREM sleep. Optogenetic stimulation of the locus coeruleus induced anti-correlated changes in vasomotion and CSF signal. Furthermore, stimulation of arterial oscillations enhanced CSF inflow, demonstrating that vasomotion acts as a pump driving CSF into the brain. On the contrary, the sleep aid zolpidem suppressed norepinephrine oscillations and glymphatic flow, highlighting the critical role of norepinephrine-driven vascular dynamics in brain clearance. Thus, the micro-architectural organization of NREM sleep, driven by norepinephrine fluctuations and vascular dynamics, is a key determinant for glymphatic clearance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39788123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39788123</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.027>10.1016/j.cell.2024.11.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39788123</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Natalie L Hauglund</dc:creator>
<dc:creator>Mie Andersen</dc:creator>
<dc:creator>Klaudia Tokarska</dc:creator>
<dc:creator>Tessa Radovanovic</dc:creator>
<dc:creator>Celia Kjaerby</dc:creator>
<dc:creator>Frederikke L Sørensen</dc:creator>
<dc:creator>Zuzanna Bojarowska</dc:creator>
<dc:creator>Verena Untiet</dc:creator>
<dc:creator>Sheyla B Ballestero</dc:creator>
<dc:creator>Mie G Kolmos</dc:creator>
<dc:creator>Pia Weikop</dc:creator>
<dc:creator>Hajime Hirase</dc:creator>
<dc:creator>Maiken Nedergaard</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep</dc:title>
<dc:identifier>pmid:39788123</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.027</dc:identifier>
</item>
<item>
<title>Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this European cohort, the lifetime risk of developing HFrEF was greater in men than in women, while women were at greater risk of developing HFpEF. Eight directly and indirectly modifiable risk factors substantially accounted for the risk of developing HFrEF and HFpEF, particularly in women.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae868. doi: 10.1093/eurheartj/ehae868. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Current estimates for the lifetime risk to develop heart failure with either a reduced (HFrEF) or preserved ejection fraction (HFpEF) and their associated risk factors are derived from two studies from the USA. The sex-specific lifetime risk and population attributable fraction of potentially modifiable risk factors for incident HFpEF and HFrEF are described in a large European community-based cohort with 25 years of follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 8558 participants from the PREVEND cohort were studied at baseline from 1997 onwards and followed until 2022 for cases of new-onset HFrEF (ejection fraction &lt; 50%) and HFpEF (ejection fraction ≥ 50%) by assessment of hospital records.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 804 cases of new-onset HF were identified (534 HFrEF and 270 HFpEF) during 25 years of follow-up. The mean age at baseline was 50 years for men and 47 years for women. The mean age at onset of HF was 72.1 years in men and 74.2 years in women. The overall lifetime risk of developing HF was 24.5% in men compared to 23.3% in women. The lifetime risk of HFrEF was lower in women compared with men (11.9% vs. 18.1%), while the lifetime risk of HFpEF was higher in women compared with men (11.5% vs. 6.4%). In women, 71% of incident HFrEF cases were attributable to eight risk factors (hypertension, hypercholesterolaemia, obesity, smoking, atrial fibrillation, chronic kidney disease, myocardial infarction, and diabetes mellitus) and 60% in men. In women, 64% of incident HFpEF cases were attributable to those risk factors, whereas this was 46% in men. More specifically, in both men and women, hypertension and hypercholesterolaemia were the strongest risk factors for HFrEF, whereas hypertension and obesity were the strongest risk factors for HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this European cohort, the lifetime risk of developing HFrEF was greater in men than in women, while women were at greater risk of developing HFpEF. Eight directly and indirectly modifiable risk factors substantially accounted for the risk of developing HFrEF and HFpEF, particularly in women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39786471</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae868>10.1093/eurheartj/ehae868</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786471</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Bart J van Essen</dc:creator>
<dc:creator>Johanna E Emmens</dc:creator>
<dc:creator>Jasper Tromp</dc:creator>
<dc:creator>Wouter Ouwerkerk</dc:creator>
<dc:creator>Marcelle D Smit</dc:creator>
<dc:creator>Christiane A Geluk</dc:creator>
<dc:creator>Lukas Baumhove</dc:creator>
<dc:creator>Navin Suthahar</dc:creator>
<dc:creator>Ron T Gansevoort</dc:creator>
<dc:creator>Stephan J L Bakker</dc:creator>
<dc:creator>Kevin Damman</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years</dc:title>
<dc:identifier>pmid:39786471</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae868</dc:identifier>
</item>
<item>
<title>Hospitalized upper extremity artery disease patients: treatment and long-term outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Upper extremity artery disease patients, irrespective of the underlying disease type, face a poor prognosis with elevated proportion of amputation and mortality. Male sex was linked to increased risk of future cardiovascular and limb events including death. Further investigation is warranted to understand the underlying causes of the sex-related disparities and identify treatment improvements.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae904. doi: 10.1093/eurheartj/ehae904. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Current knowledge about upper extremity artery disease (UEAD) is scarce. This study aimed to evaluate the prevalence, treatment patterns, and short- and long-term outcomes of patients suffering from UEAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Retrospective health claims data of patients who were hospitalized with a primary diagnosis of UEAD between 2010 and 2017 were analysed. The data were obtained from 11 legally independent statutory health insurance funds of the 'AOK-Die Gesundheitskasse'. Risk factors, comorbidities, pharmacotherapy, revascularization procedure, and outcome were evaluated with a particular focus on sex-related disparities (median follow-up time: 5.5 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 2437 UEAD patients (43% female, median age of 67 years), 80% were solely atherosclerotic (UEADa), while 20% had concomitant inflammatory/connective tissue diseases (UEADc/i). Cardiovascular risk factors and comorbidities were highly prevalent in both sexes. Coronary, cerebrovascular, and lower extremity artery diseases and organ failure such as chronic kidney and heart failure were more frequent in men compared with women. At index stay, women had higher rate of revascularization than men (37% vs. 27%). The 5 year mortality among the entire population was almost 50%, even higher in men (UEADa: 51% vs. 36% P &lt; .001; UEADc/i: 44% vs. 36%, P &lt; .05). Furthermore, men had higher rates of upper limb amputation compared with women despite equal secondary preventive pharmacotherapy (UEADa: 26% vs. 11%, P &lt; .001; UEADc/i: 30% vs. 18%, P &lt; .01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Upper extremity artery disease patients, irrespective of the underlying disease type, face a poor prognosis with elevated proportion of amputation and mortality. Male sex was linked to increased risk of future cardiovascular and limb events including death. Further investigation is warranted to understand the underlying causes of the sex-related disparities and identify treatment improvements.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39786470</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae904>10.1093/eurheartj/ehae904</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786470</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Lena Makowski</dc:creator>
<dc:creator>Christiane Engelbertz</dc:creator>
<dc:creator>Jeanette Köppe</dc:creator>
<dc:creator>Patrik Dröge</dc:creator>
<dc:creator>Thomas Ruhnke</dc:creator>
<dc:creator>Christian Günster</dc:creator>
<dc:creator>Joachim Gerß</dc:creator>
<dc:creator>Eva Freisinger</dc:creator>
<dc:creator>Nasser Malyar</dc:creator>
<dc:creator>Holger Reinecke</dc:creator>
<dc:creator>Jannik Feld</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hospitalized upper extremity artery disease patients: treatment and long-term outcomes</dc:title>
<dc:identifier>pmid:39786470</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae904</dc:identifier>
</item>
<item>
<title>Multiple simultaneous coronary plaque erosion detected by optical coherence tomography associated with systemic lupus erythematosus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786444/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae899. doi: 10.1093/eurheartj/ehae899. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786444/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39786444</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae899>10.1093/eurheartj/ehae899</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786444</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Lina Cui</dc:creator>
<dc:creator>Chao Fang</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multiple simultaneous coronary plaque erosion detected by optical coherence tomography associated with systemic lupus erythematosus</dc:title>
<dc:identifier>pmid:39786444</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae899</dc:identifier>
</item>
<item>
<title>Mechanism of syncope: role of ambulatory blood pressure monitoring and cardiovascular autonomic function assessment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The standardized 2STEPS protocol offers an easy-to-perform and time-saving diagnostic work-up allowing identification of the haemodynamic mechanism of loss of consciousness in most patients with autonomic syncope. This protocol provides the necessary background for a personalized mechanism-specific therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae907. doi: 10.1093/eurheartj/ehae907. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Identifying the haemodynamic mechanism of autonomic syncope is the essential pre-requisite for effective and personalized therapy aimed at preventing recurrences. The present study assessed the diagnostic efficacy of a two-step assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Multicentre prospective, cross-sectional, observational study. Patients affected by severe autonomic syncope underwent a two-step assessment including 24-h ambulatory blood pressure monitoring and short cardiovascular autonomic function assessment (SCAFA). SCAFA consisted of carotid sinus massage (CSM), performed in patients ≥40 years old, a passive standing test, and a 'fast' head-up tilt test scheduled sequentially during one session on a tilt table.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study population consisted of 333 patients, 102 ≤ 40 years old and 231 >; 40 years old. Any positive response was observed in 298 (89%) patients (92 [92%] in younger and 134 [89%] in older), with hypotensive phenotype accounting for 226 (68%), bradycardic phenotype for 21 (6%) and mixed phenotype for 51 (15%) of cases. The mean duration of the SCAFA procedure was 25 (IQR 20-32) min. Ambulatory blood pressure monitoring, CSM, passive standing, and head-up tilt test were positive in 60%, 15%, 3%, and 71% of patients, respectively. More than one test was positive in 51% and 49% of patients ≤40 and >;40 years, respectively. Large inter-centre variability of CSM positivity rate, which remained significant after adjustment for demographic and clinical variables, was observed (P = .003).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The standardized 2STEPS protocol offers an easy-to-perform and time-saving diagnostic work-up allowing identification of the haemodynamic mechanism of loss of consciousness in most patients with autonomic syncope. This protocol provides the necessary background for a personalized mechanism-specific therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39786439</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae907>10.1093/eurheartj/ehae907</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786439</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Antonella Groppelli</dc:creator>
<dc:creator>Vincenzo Russo</dc:creator>
<dc:creator>Erika Parente</dc:creator>
<dc:creator>Angelo Comune</dc:creator>
<dc:creator>Frederik J de Lange</dc:creator>
<dc:creator>Giulia Rivasi</dc:creator>
<dc:creator>Martina Rafanelli</dc:creator>
<dc:creator>Jean Claude Deharo</dc:creator>
<dc:creator>Jaume Francisco-Pascual</dc:creator>
<dc:creator>Roberto Maggi</dc:creator>
<dc:creator>Artur Fedorowski</dc:creator>
<dc:creator>Andrea Ungar</dc:creator>
<dc:creator>Gianfranco Parati</dc:creator>
<dc:creator>Michele Brignole</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mechanism of syncope: role of ambulatory blood pressure monitoring and cardiovascular autonomic function assessment</dc:title>
<dc:identifier>pmid:39786439</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae907</dc:identifier>
</item>
<item>
<title>Rate dependent complete right bundle block: a challenging diagnosis in Brugada syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae921. doi: 10.1093/eurheartj/ehae921. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39786427</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae921>10.1093/eurheartj/ehae921</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786427</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jing Yang</dc:creator>
<dc:creator>Rong He</dc:creator>
<dc:creator>Ping Zhang</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rate dependent complete right bundle block: a challenging diagnosis in Brugada syndrome</dc:title>
<dc:identifier>pmid:39786427</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae921</dc:identifier>
</item>
<item>
<title>Recurrent plaque erosion is linked to biomechanical conditions: insight from optical coherence tomography-based fluid-structure interaction models</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786425/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae903. doi: 10.1093/eurheartj/ehae903. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786425/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39786425</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae903>10.1093/eurheartj/ehae903</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786425</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Haibo Jia</dc:creator>
<dc:creator>Liang Wang</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Recurrent plaque erosion is linked to biomechanical conditions: insight from optical coherence tomography-based fluid-structure interaction models</dc:title>
<dc:identifier>pmid:39786425</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae903</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: no CLEAR evidence of cardiovascular benefits of colchicine after acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786152/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae897. doi: 10.1093/eurheartj/ehae897. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786152/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39786152</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae897>10.1093/eurheartj/ehae897</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786152</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: no CLEAR evidence of cardiovascular benefits of colchicine after acute myocardial infarction</dc:title>
<dc:identifier>pmid:39786152</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae897</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: the (BP)ROAD to optimal blood pressure control in type-2 diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786145/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae894. doi: 10.1093/eurheartj/ehae894. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786145/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39786145</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae894>10.1093/eurheartj/ehae894</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786145</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: the (BP)ROAD to optimal blood pressure control in type-2 diabetes</dc:title>
<dc:identifier>pmid:39786145</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae894</dc:identifier>
</item>
<item>
<title>Coronary revascularization in the NOTION-2 trial: an in-depth data analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39783784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae763. doi: 10.1093/eurheartj/ehae763. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39783784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39783784</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae763>10.1093/eurheartj/ehae763</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39783784</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Troels Højsgaard Jørgensen</dc:creator>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary revascularization in the NOTION-2 trial: an in-depth data analysis</dc:title>
<dc:identifier>pmid:39783784</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae763</dc:identifier>
</item>
<item>
<title>Coronary revascularization in randomized clinical trials comparing transcatheter and surgical aortic valve replacement: is it time to bridge the gap?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39783766/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae762. doi: 10.1093/eurheartj/ehae762. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39783766/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39783766</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae762>10.1093/eurheartj/ehae762</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39783766</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Hugo M Aarts</dc:creator>
<dc:creator>Michiel Voskuil</dc:creator>
<dc:creator>Ronak Delewi</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary revascularization in randomized clinical trials comparing transcatheter and surgical aortic valve replacement: is it time to bridge the gap?</dc:title>
<dc:identifier>pmid:39783766</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae762</dc:identifier>
</item>
<item>
<title>Non-oncologic metastases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39783660/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae211. doi: 10.1093/eurheartj/ehae211. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39783660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39783660</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae211>10.1093/eurheartj/ehae211</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39783660</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Dina Fernandes Neto</dc:creator>
<dc:creator>Maria Melendo-Viu</dc:creator>
<dc:creator>Cristina Gomez-Varela</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-oncologic metastases</dc:title>
<dc:identifier>pmid:39783660</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae211</dc:identifier>
</item>
<item>
<title>PIEZO1 as a potential therapeutic target in Marfan syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39783624/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250111011355&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae882. doi: 10.1093/eurheartj/ehae882. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39783624/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250111011355&v=2.18.0.post9+e462414">39783624</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae882>10.1093/eurheartj/ehae882</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39783624</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jin Komuro</dc:creator>
<dc:creator>Norifumi Takeda</dc:creator>
<dc:creator>Issei Komuro</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>PIEZO1 as a potential therapeutic target in Marfan syndrome</dc:title>
<dc:identifier>pmid:39783624</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae882</dc:identifier>
</item>





























</channel>
</rss>